A glyco-dendrimer-based anti-tumor vaccine with dual CLR (DC-SIGN, Langerin) targeting was prepared for the targeting of multiple skin DC subsets for improved anti-tumor therapy. The gene discussed is CD209; the disease is neoplasm.